Journal of Immunology Research / 2018 / Article / Tab 1 / Review Article
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials Table 1 Baseline characteristics of the included studies.
Study/reference Phase Number of patients Treatment regimens Median follow-up (months) Primary endpoint Median PFS (months) 1-year PFS rate (%) Median OS (months) 1-year OS rate (%) Palumbo et al. (2016) (CASTOR) III 498 E: daratumumab 16 mg/kg + bortezomib 1.3 mg/m2 + dexamethasone 20 mg C: bortezomib 1.3 mg/m2 + dexamethasone 20 mg E: 7.4 C: 7.4 PFS E: NA C: 7.2 E: 60.7% C: 26.9% E: NA C: NA E: NA C: NA Dimopoulos et al. (2016) (POLLUX) III 569 E: daratumumab 16 mg/kg + lenalidomide 25 mg + dexamethasone 40 mg C: lenalidomide 25 mg + dexamethasone 40 mg E: 13.5 C: 13.5 PFS E: NA C: 18.4 E: 83.2% C: 60.1% E: NA C: NA E: 92.1% C: 86.8% Lonial et al. (2015) (ELOQUENT-2) Dimopoulos et al. (2017) (ELOQUENT-2 follow-up) III 646 E: elotuzumab 10 mg/kg + lenalidomide 25 mg + dexamethasone 40 mg C: lenalidomide 25 mg + dexamethasone 40 mg E: 24.5 C: 24.5 PFS E: 19.4 C: 14.9 E: 1-year PFS rate 68%; 2-year PFS rate 41% C: 1-year PFS rate 57% 2-year PFS rate 27% E: 43.7 C: 39.6 E: 1-year OS rate 91%; 2-year OS rate 73% C: 1-year OS rate 83% 2-year OS rate 69% Jakubowiak et al. (2016) (NCT01478048 ) II 152 E: elotuzumab 10 mg/kg + bortezomib 1.3 mg/m2 + dexamethasone 20 mg C: bortezomib 1.3 mg/m2 + dexamethasone 20 mg E: 15.9 C: 11.7 PFS E: 9.7 C: 6.9 E: 1-year PFS rate 39%; 2-year PFS rate 18% C: 1-year PFS rate 33% 2-year PFS rate 11% E: NA C: NA E: 1-year OS rate 85%; 2-year OS rate 73% C: 1-year OS rate 74% 2-year OS rate 66% San-Miguel et al. (2014) (PANORAMA1) San-Miguel et al. (2016) (PANORAMA1 follow-up) III 768 E: panobinostat 20 mg + bortezomib 1.3 mg/m2 + dexamethasone 20 mg C: placebo + bortezomib 1.3 mg/m2 + dexamethasone 20 mg E: 6.47 C: 5.59 PFS E: 11.99 C: 8.08 E: 2-year PFS rate 20.6% C: 2-year PFS rate 8.4% E: 40.3 C: 35.8 E: NA C: NA Dimopoulos et al. (2013) (VANTAGE088) III 637 E: vorinostat 400 mg + bortezomib 1.3 mg/m2 C: placebo + bortezomib 1.3 mg/m2 E: 14.2 C: 14.2 PFS E: 7.63 C: 6.83 E: NA C: NA E: NA C: 28.07 E: NA C: NA
PFS: progression-free survival; OS: overall survival; E: experimental group; C: control group; NA: not available.